|
|
Vaccine Detail
|
NIMENRIX |
| Vaccine Information |
- Vaccine Name: NIMENRIX
- Target Pathogen: Neisseria meningitidis
- Target Disease: Meningitis
- Product Name: Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine
- Tradename: NIMENRIX
- Manufacturer: Pfizer Inc.
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: Canada
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store at 2°C to 8°C (36°F to 46°F), do not freeze, and protect from light.
- Approved Age for Licensed Use: 1 to 55 years of age.
- Description: NIMENRIX® (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) is a tetravalent meningococcal polysaccharide conjugated vaccine consisting of Neisseria
meningitidis capsular polysaccharides A, C, W-135 and Y each coupled to tetanus toxoid as a carrier protein. The Neisseria meningitidis serogroups A and C polysaccharides are conjugated with an adipic dihydrazide (AH) spacer and indirectly conjugated to the tetanus toxoid whereas the W-135 and Y polysaccharides are conjugated directly to tetanus toxoid. (Pfizer: NIMENRIX)
|
| Host Response |
|
|
| References |
Pfizer: NIMENRIX: Pfizer: NIMENRIX vaccine information [http://www.pfizer.ca/sites/g/files/g10028126/f/201604/Nimenrix_PM_184020_23Mar2016_E.pdf]
|
|
